handshake-istock-512549722-choreograph-
Choreograph / iStockphoto.com
31 May 2017Americas

Janssen enters into licence with Protagonist

Janssen Biotech has entered into a worldwide exclusive licence and collaboration agreement with US-based Protagonist Therapeutics.

The licence will focus on commercialising a treatment, called PTG-200, for Crohn’s disease and ulcerative colitis.

Under the terms of the agreement, Protagonist will receive an upfront payment. It is also eligible to receive development and commercialisation milestone payments.

According to a statement released yesterday, if PTG-200 is commercialised, Protagonist will also be eligible to receive royalties on net sales.

Susan Dillon, global therapeutic area head at Janssen, said: “Together with Johnson & Johnson Innovation, we have forged a strong relationship with the Protagonist Therapeutics team over the course of several years.

Janssen is a subsidiary of Johnson & Johnson.

“We look forward to continuing a strong and productive collaboration in progressing this novel oral candidate for the treatment of inflammatory bowel disease.”

Dinesh Patel, CEO of Protagonist, said: “We are very pleased to partner with Janssen, a world-leader in the development of innovative therapies for patients suffering with chronic inflammatory and immunomodulatory diseases. As an oral IL-23 receptor antagonist, PTG-200 nicely complements Janssen's current IBD portfolio.”

The transaction is expected to close in the third quarter of 2017.

Today’s stories:

Boehringer takes on FTC over privilege

Fed Circuit vacates and remands PTAB’s decision

Appleyard Lees appoints partner in Cambridge, UK

UK Court rejects request for summary judgment

Did you enjoy reading this story?  Sign up to our free newsletters and get stories like this sent straight to your inbox.